Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has earned an average rating of “Moderate Buy” from the twenty-three brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $1,037.33.

Several research firms have commented on REGN. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Royal Bank of Canada lowered their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of REGN. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $39,000. Finally, Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 5.0 %

Shares of NASDAQ:REGN opened at $696.88 on Monday. The business has a 50-day moving average price of $751.44 and a 200-day moving average price of $961.06. The stock has a market cap of $76.58 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals has a 52-week low of $691.00 and a 52-week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.